Generation of human monoclonal antibodies reactive with cellular antigens

Richard J Cote, D. M. Morrissey, A. N. Houghton, E. J. Beattie, H. F. Oettgen, L. J. Old

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Human lymphocytes from lymph node, peripheral blood, spleen, and tumor specimens have been fused with the LICR-LON-HMy2 (LICR-2) or SKO-007 human cell lines or the NS-1 mouse myeloma line. Over 75 fusions with the three myeloma-lymphoblastoid lines have been performed. Several factors appeared to improve the fusion outcome, including maintenance of the myeloma-lymphoblastoid lines in logarithmic phase growth at ≥ 95% viability, a delay of 24 hr in the introduction of aminopterin to the fused cells, and preselection of the fetal calf serum used in the medium. For a given number of lymphocytes, fusions with NS-1 produced 5-20 times more clones than fusions with LICR-2 or SKO-007, and LICR-2 produced 4 times as many clones as SKO-007. The percentage of clones secreting human immunoglobulin, the range of immunoglobulin production, and the proportion of IgM, IgA, and IgG secretors were comparable for clones derived from the three myeloma-lymphoblastoid lines. Stable Ig-secreting clones were isolated with approximately equal frequency from LICR-2 and NS-1 fusions. A number of stable clones producing human monoclonal antibodies reacting with cell-surface, cytoplasmic, or nuclear antigens have been isolated from tumor-bearing patients and normal individuals. A surface antigenic system present on normal and malignant cells has been defined with a human monoclonal antibody derived from a patient with breast cancer. Techniques for producing human monoclonal antibody now appear to be sufficiently advanced to initiate a serological dissection of the humoral immune response to cancer.

Original languageEnglish
Pages (from-to)2026-2030
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume80
Issue number7 I
StatePublished - Sep 23 1983
Externally publishedYes

Fingerprint

Clone Cells
Monoclonal Antibodies
Antigens
Immunoglobulins
Aminopterin
Neoplasms
Nuclear Antigens
Lymphocyte Count
Surface Antigens
Humoral Immunity
Immunoglobulin A
Immunoglobulin M
Dissection
Spleen
Immunoglobulin G
Lymph Nodes
Maintenance
Lymphocytes
Breast Neoplasms
Cell Line

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cote, R. J., Morrissey, D. M., Houghton, A. N., Beattie, E. J., Oettgen, H. F., & Old, L. J. (1983). Generation of human monoclonal antibodies reactive with cellular antigens. Proceedings of the National Academy of Sciences of the United States of America, 80(7 I), 2026-2030.

Generation of human monoclonal antibodies reactive with cellular antigens. / Cote, Richard J; Morrissey, D. M.; Houghton, A. N.; Beattie, E. J.; Oettgen, H. F.; Old, L. J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 80, No. 7 I, 23.09.1983, p. 2026-2030.

Research output: Contribution to journalArticle

Cote, RJ, Morrissey, DM, Houghton, AN, Beattie, EJ, Oettgen, HF & Old, LJ 1983, 'Generation of human monoclonal antibodies reactive with cellular antigens', Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 7 I, pp. 2026-2030.
Cote, Richard J ; Morrissey, D. M. ; Houghton, A. N. ; Beattie, E. J. ; Oettgen, H. F. ; Old, L. J. / Generation of human monoclonal antibodies reactive with cellular antigens. In: Proceedings of the National Academy of Sciences of the United States of America. 1983 ; Vol. 80, No. 7 I. pp. 2026-2030.
@article{9af14030ef6b4c89b158ec4c99dea3bf,
title = "Generation of human monoclonal antibodies reactive with cellular antigens",
abstract = "Human lymphocytes from lymph node, peripheral blood, spleen, and tumor specimens have been fused with the LICR-LON-HMy2 (LICR-2) or SKO-007 human cell lines or the NS-1 mouse myeloma line. Over 75 fusions with the three myeloma-lymphoblastoid lines have been performed. Several factors appeared to improve the fusion outcome, including maintenance of the myeloma-lymphoblastoid lines in logarithmic phase growth at ≥ 95{\%} viability, a delay of 24 hr in the introduction of aminopterin to the fused cells, and preselection of the fetal calf serum used in the medium. For a given number of lymphocytes, fusions with NS-1 produced 5-20 times more clones than fusions with LICR-2 or SKO-007, and LICR-2 produced 4 times as many clones as SKO-007. The percentage of clones secreting human immunoglobulin, the range of immunoglobulin production, and the proportion of IgM, IgA, and IgG secretors were comparable for clones derived from the three myeloma-lymphoblastoid lines. Stable Ig-secreting clones were isolated with approximately equal frequency from LICR-2 and NS-1 fusions. A number of stable clones producing human monoclonal antibodies reacting with cell-surface, cytoplasmic, or nuclear antigens have been isolated from tumor-bearing patients and normal individuals. A surface antigenic system present on normal and malignant cells has been defined with a human monoclonal antibody derived from a patient with breast cancer. Techniques for producing human monoclonal antibody now appear to be sufficiently advanced to initiate a serological dissection of the humoral immune response to cancer.",
author = "Cote, {Richard J} and Morrissey, {D. M.} and Houghton, {A. N.} and Beattie, {E. J.} and Oettgen, {H. F.} and Old, {L. J.}",
year = "1983",
month = "9",
day = "23",
language = "English",
volume = "80",
pages = "2026--2030",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7 I",

}

TY - JOUR

T1 - Generation of human monoclonal antibodies reactive with cellular antigens

AU - Cote, Richard J

AU - Morrissey, D. M.

AU - Houghton, A. N.

AU - Beattie, E. J.

AU - Oettgen, H. F.

AU - Old, L. J.

PY - 1983/9/23

Y1 - 1983/9/23

N2 - Human lymphocytes from lymph node, peripheral blood, spleen, and tumor specimens have been fused with the LICR-LON-HMy2 (LICR-2) or SKO-007 human cell lines or the NS-1 mouse myeloma line. Over 75 fusions with the three myeloma-lymphoblastoid lines have been performed. Several factors appeared to improve the fusion outcome, including maintenance of the myeloma-lymphoblastoid lines in logarithmic phase growth at ≥ 95% viability, a delay of 24 hr in the introduction of aminopterin to the fused cells, and preselection of the fetal calf serum used in the medium. For a given number of lymphocytes, fusions with NS-1 produced 5-20 times more clones than fusions with LICR-2 or SKO-007, and LICR-2 produced 4 times as many clones as SKO-007. The percentage of clones secreting human immunoglobulin, the range of immunoglobulin production, and the proportion of IgM, IgA, and IgG secretors were comparable for clones derived from the three myeloma-lymphoblastoid lines. Stable Ig-secreting clones were isolated with approximately equal frequency from LICR-2 and NS-1 fusions. A number of stable clones producing human monoclonal antibodies reacting with cell-surface, cytoplasmic, or nuclear antigens have been isolated from tumor-bearing patients and normal individuals. A surface antigenic system present on normal and malignant cells has been defined with a human monoclonal antibody derived from a patient with breast cancer. Techniques for producing human monoclonal antibody now appear to be sufficiently advanced to initiate a serological dissection of the humoral immune response to cancer.

AB - Human lymphocytes from lymph node, peripheral blood, spleen, and tumor specimens have been fused with the LICR-LON-HMy2 (LICR-2) or SKO-007 human cell lines or the NS-1 mouse myeloma line. Over 75 fusions with the three myeloma-lymphoblastoid lines have been performed. Several factors appeared to improve the fusion outcome, including maintenance of the myeloma-lymphoblastoid lines in logarithmic phase growth at ≥ 95% viability, a delay of 24 hr in the introduction of aminopterin to the fused cells, and preselection of the fetal calf serum used in the medium. For a given number of lymphocytes, fusions with NS-1 produced 5-20 times more clones than fusions with LICR-2 or SKO-007, and LICR-2 produced 4 times as many clones as SKO-007. The percentage of clones secreting human immunoglobulin, the range of immunoglobulin production, and the proportion of IgM, IgA, and IgG secretors were comparable for clones derived from the three myeloma-lymphoblastoid lines. Stable Ig-secreting clones were isolated with approximately equal frequency from LICR-2 and NS-1 fusions. A number of stable clones producing human monoclonal antibodies reacting with cell-surface, cytoplasmic, or nuclear antigens have been isolated from tumor-bearing patients and normal individuals. A surface antigenic system present on normal and malignant cells has been defined with a human monoclonal antibody derived from a patient with breast cancer. Techniques for producing human monoclonal antibody now appear to be sufficiently advanced to initiate a serological dissection of the humoral immune response to cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020526392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020526392&partnerID=8YFLogxK

M3 - Article

C2 - 6572959

AN - SCOPUS:0020526392

VL - 80

SP - 2026

EP - 2030

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7 I

ER -